Suzhou Zelgen BiopharmaceuticalsLtd Balance Sheet Health
Financial Health criteria checks 4/6
Suzhou Zelgen BiopharmaceuticalsLtd has a total shareholder equity of CN¥1.3B and total debt of CN¥893.5M, which brings its debt-to-equity ratio to 68.6%. Its total assets and total liabilities are CN¥3.0B and CN¥1.7B respectively.
Key information
68.6%
Debt to equity ratio
CN¥893.53m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥2.20b |
| Equity | CN¥1.30b |
| Total liabilities | CN¥1.66b |
| Total assets | CN¥2.97b |
Recent financial health updates
No updates
Recent updates
Some Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Analysts Just Made A Major Cut To Next Year's Estimates
Sep 11
What Does The Future Hold For Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266)? These Analysts Have Been Cutting Their Estimates
May 08Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Shares Climb 28% But Its Business Is Yet to Catch Up
Mar 06Financial Position Analysis
Short Term Liabilities: 688266's short term assets (CN¥2.6B) exceed its short term liabilities (CN¥1.3B).
Long Term Liabilities: 688266's short term assets (CN¥2.6B) exceed its long term liabilities (CN¥350.7M).
Debt to Equity History and Analysis
Debt Level: 688266 has more cash than its total debt.
Reducing Debt: 688266's debt to equity ratio has increased from 15.1% to 68.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 688266 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 688266 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.